Sort by
Refine Your Search
-
Start Date: Between 1 August 2026 and 1 July 2027 Introduction: This PhD is aligned with an exciting new multi-centre research programme on parallel mesh generation for advancing cutting-edge high
-
to neuronal dysfunction and degeneration in HD. In parallel, epitranscriptomic mechanisms, particularly N6-methyladenosine (m6A) RNA methylation, have emerged as key regulators of neuronal homeostasis, but
-
access restrictions. In parallel, AI-driven services are increasingly deployed in a distributed fashion, with inference spread across cloud, enterprise domains, and edge locations close to data sources and
-
vendors, each with their own management interfaces, data formats, and access restrictions. In parallel, AI-driven services are increasingly deployed in a distributed fashion, with inference spread across
-
Centre Euopéen de Recherche et de Formation Avancée en Calcul Scientifique (CERFACS) | Toulouse, Midi Pyrenees | France | 18 days ago
). It hosts several scientific teams covering several topics (climatology, fluid mechanics, parallel algorithms...) among which the CFD (Computational Fluid Dynamics) team is the largest. The main fields
-
degradation will be measured. In parallel, field-based measurements will be made of protein degradation pathways, and growth/protein synthesis proxies in wild fish at times of high and low sea temperature, in
-
) The Institute of Computer Engineering (ZITI) at Heidelberg University invites applications for one research assistant position with the possibility to do a PhD in parallel at the chair of computer architecture
-
. The interaction between the experimental project and the parallel modelling project, focused on simulating particle generation in silicon wafers, is therefore essential. Section Mechanics of Materials You will work
-
materials with engineered catalytic sites, as part of the HyCARB project. The successful candidate will join a dynamic research team with access to facilities for materials synthesis and parallel catalytic
-
technologies, drug discovery and advanced therapeutics. We have excellent facilities to support our parallel use of pre-clinical cell and in vivo models, alongside human cellular models, which provide